Mia Schmidt-Hansen1, Sabine Berendse2, William Hamilton3. 1. National Collaborating Centre for Cancer, Park House, Greyfriars Road, Cardiff CF10 3AF and Mia.Schmidt-Hansen@wales.nhs.uk. 2. National Collaborating Centre for Cancer, Park House, Greyfriars Road, Cardiff CF10 3AF and. 3. University of Exeter Medical School, College House, Magdalen Road, Exeter EX1 2LU, UK.
Abstract
BACKGROUND: We performed a systematic review of diagnostic studies of symptomatic patients in primary care to quantify the risk of brain/central nervous system (CNS) cancer in patients presenting in primary care with symptoms that may indicate brain/CNS cancer. OBJECTIVE: To quantify the risk of brain/CNS cancer in symptomatic patients presenting in primary care. METHODS: We searched Medline, Premedline, Embase, the Cochrane Library, Web of Science and ISI Proceedings (1980 to August 2014) and PsychInfo (1980 to February 2013) for diagnostic studies of symptomatic adult patients in primary care. Study quality was assessed using QUADAS-II and data were extracted to calculate the positive predictive values (PPVs) of symptoms, singly or in combination, for brain/CNS cancer. RESULTS: Six studies with 159938 patients were included. The PPVs of single symptoms were very low with only 'new-onset seizure' being above 1% in patients aged 18 years and above, rising to 2.3% in patients aged 60-69 years. In patients aged 15-24 years, the PPVs for the individual symptoms were also very low, with the highest, also for seizure, being 0.024%, similar to that in children aged 0-14 years of 0.02%. For symptom combinations, none of the PPVs were above 0.39%. CONCLUSIONS: All the symptoms of brain tumours are individually low risk, apart from new-onset epilepsy. This provides a real diagnostic problem, as brain tumours have all the expected features seen with cancer diagnostic delay, with high proportions presenting as an emergency and having had multiple primary care consultations before referral, and the prognosis is poor. Improving these metrics can only be done by liberalizing investigation, although the health economics of that strategy is undetermined.
BACKGROUND: We performed a systematic review of diagnostic studies of symptomatic patients in primary care to quantify the risk of brain/central nervous system (CNS) cancer in patients presenting in primary care with symptoms that may indicate brain/CNS cancer. OBJECTIVE: To quantify the risk of brain/CNS cancer in symptomatic patients presenting in primary care. METHODS: We searched Medline, Premedline, Embase, the Cochrane Library, Web of Science and ISI Proceedings (1980 to August 2014) and PsychInfo (1980 to February 2013) for diagnostic studies of symptomatic adult patients in primary care. Study quality was assessed using QUADAS-II and data were extracted to calculate the positive predictive values (PPVs) of symptoms, singly or in combination, for brain/CNS cancer. RESULTS: Six studies with 159938 patients were included. The PPVs of single symptoms were very low with only 'new-onset seizure' being above 1% in patients aged 18 years and above, rising to 2.3% in patients aged 60-69 years. In patients aged 15-24 years, the PPVs for the individual symptoms were also very low, with the highest, also for seizure, being 0.024%, similar to that in children aged 0-14 years of 0.02%. For symptom combinations, none of the PPVs were above 0.39%. CONCLUSIONS: All the symptoms of brain tumours are individually low risk, apart from new-onset epilepsy. This provides a real diagnostic problem, as brain tumours have all the expected features seen with cancer diagnostic delay, with high proportions presenting as an emergency and having had multiple primary care consultations before referral, and the prognosis is poor. Improving these metrics can only be done by liberalizing investigation, although the health economics of that strategy is undetermined.
Authors: Judith Schwartzbaum; Fredrik Jonsson; Anders Ahlbom; Susan Preston-Martin; Beatrice Malmer; Stefan Lönn; Karin Söderberg; Maria Feychting Journal: Cancer Epidemiol Biomarkers Prev Date: 2005-03 Impact factor: 4.254
Authors: Penny F Whiting; Anne W S Rutjes; Marie E Westwood; Susan Mallett; Jonathan J Deeks; Johannes B Reitsma; Mariska M G Leeflang; Jonathan A C Sterne; Patrick M M Bossuyt Journal: Ann Intern Med Date: 2011-10-18 Impact factor: 25.391
Authors: Sarah J Price; Elizabeth A Shephard; Sally A Stapley; Kevin Barraclough; William T Hamilton Journal: Br J Gen Pract Date: 2014-09 Impact factor: 5.386
Authors: Kathreena M Kurian; Michael D Jenkinson; Paul M Brennan; Robin Grant; Sarah Jefferies; Alasdair G Rooney; Helen Bulbeck; Sara C Erridge; Samantha Mills; Catherine McBain; Martin G McCabe; Stephen J Price; Silvia Marino; Erica Moyes; Wendy Qian; Adam Waldman; Babar Vaqas; Debbie Keatley; Peter Burchill; Colin Watts Journal: Neurooncol Pract Date: 2017-08-30
Authors: Marthe C M Peeters; Linda Dirven; Johan A F Koekkoek; Ellen G Gortmaker; Lara Fritz; Maaike J Vos; Martin J B Taphoorn Journal: J Neurooncol Date: 2020-01-01 Impact factor: 4.130
Authors: Robin Grant; Therese Dowswell; Eve Tomlinson; Paul M Brennan; Fiona M Walter; Yoav Ben-Shlomo; David William Hunt; Helen Bulbeck; Ashleigh Kernohan; Tomos Robinson; Theresa A Lawrie Journal: Cochrane Database Syst Rev Date: 2020-09-04
Authors: Mio Ozawa; Paul M Brennan; Karolis Zienius; Kathreena M Kurian; William Hollingworth; David Weller; Willie Hamilton; Robin Grant; Yoav Ben-Shlomo Journal: Fam Pract Date: 2018-09-18 Impact factor: 2.267
Authors: Fiona M Walter; Clarissa Penfold; Alexis Joannides; Smiji Saji; Margaret Johnson; Colin Watts; Andrew Brodbelt; Michael D Jenkinson; Stephen J Price; Willie Hamilton; Suzanne E Scott Journal: Br J Gen Pract Date: 2019-03-11 Impact factor: 5.386
Authors: Holly J Butler; Paul M Brennan; James M Cameron; Duncan Finlayson; Mark G Hegarty; Michael D Jenkinson; David S Palmer; Benjamin R Smith; Matthew J Baker Journal: Nat Commun Date: 2019-10-08 Impact factor: 14.919
Authors: Serena Ricci; Elia Guadagno; Dario Bruzzese; Marialaura Del Basso De Caro; Carmela Peca; Francesco G Sgulò; Francesco Maiuri; Angelina Di Carlo Journal: J Neurooncol Date: 2016-10-18 Impact factor: 4.130